{"disease":{"id":"brca2-mutation-carrier","name":"brca2 mutation carrier"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT02208375","title":"mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":159,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT01219075","title":"Soy Isoflavones Supplementation in Treating Women at High Risk For or With Breast Cancer","phase":"NA","overall_status":"COMPLETED","enrollment_count":110,"lead_sponsor_name":"University of Southern California","has_results":false},{"nct_id":"NCT00892736","title":"Veliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous Therapy","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":98,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT01540565","title":"Veliparib in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":52,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT00080756","title":"Deslorelin Combined With Low-Dose Add-Back Estradiol and Testosterone in Preventing Breast Cancer in Premenopausal Women Who Are at High Risk for This Disease","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":11,"lead_sponsor_name":"City of Hope Medical Center","has_results":false}],"total":5},"guidelines":[],"source":"Drug Landscape verified database"}